LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced that management has begun planning for its anticipated attendance at the World Health Expo 2027 in Dubai, United Arab Emirates. The move is part of a broader strategy to evaluate international healthcare expansion opportunities beyond the company's current focus on Latin America.
Management believes attendance at the expo will provide an important opportunity to engage with healthcare leaders, technology innovators, and potential strategic partners from around the world. The company aims to assess international commercialization opportunities for its developing digital healthcare ecosystem, which includes telehealth infrastructure, healthcare coordination technologies, pharmacy integration initiatives, insurance accessibility solutions, payment accessibility technologies, and artificial intelligence-driven healthcare platforms.
CEO Dr. Kevin Rodan Levy stated, 'As we continue executing our long-term vision of building an integrated digital healthcare ecosystem, we believe it is important to evaluate opportunities beyond our existing markets. World Health Expo 2027 is expected to provide an outstanding opportunity to engage with healthcare leaders from around the world, better understand evolving global healthcare trends, and explore potential strategic relationships.'
The planned participation builds upon recent international engagement initiatives, including attendance at HLTH Europe, and complements the company's continued expansion throughout Latin America. This includes recently announced strategic initiatives in Venezuela and ongoing evaluation of expansion opportunities in Colombia.
Management emphasized that attendance remains in the planning stage and forms part of broader evaluation of future international growth opportunities. No assurance can be provided regarding the completion of any strategic relationships, licensing arrangements, commercial agreements, or international expansion initiatives that may arise from the planned attendance.
Separately, the company announced that FINRA has confirmed its previously announced 5-for-1 forward stock split and mandatory share exchange are expected to become effective at the opening of trading on Wednesday, July 15, 2026, subject to completion of customary administrative processing. Shareholders holding shares through brokerage accounts or in electronic book-entry form generally are not expected to take any action, while shareholders holding physical stock certificates may exchange their certificates through the company's transfer agent.
The company looks forward to completing this important corporate milestone as it continues focusing on the expansion of its telemedicine platform and the commercialization of its CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms. For additional information, visit https://latamed.ai.
